<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>RAPID: Developing a universal modular platform to engineer coronavirus vaccine candidates</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>07/15/2020</AwardEffectiveDate>
<AwardExpirationDate>06/30/2022</AwardExpirationDate>
<AwardTotalIntnAmount>200000.00</AwardTotalIntnAmount>
<AwardAmount>200000</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>03090000</Code>
<Directorate>
<Abbreviation>MPS</Abbreviation>
<LongName>Direct For Mathematical &amp; Physical Scien</LongName>
</Directorate>
<Division>
<Abbreviation>CHE</Abbreviation>
<LongName>Division Of Chemistry</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Pui Ho</SignBlockName>
<PO_EMAI>puiho@nsf.gov</PO_EMAI>
<PO_PHON>7032920000</PO_PHON>
</ProgramOfficer>
<AbstractNarration>With this award, the Chemistry of Life Processes program in the Chemistry Division supports the studies by Dr. Angad Mehta at the University of Illinois at Urbana-Champaign to make live attenuated forms of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that require an unnatural compound to reproduce. SARS-CoV-2 is the virus that causes coronavirus disease 2019 (COVID-19). Live-attenuated viruses have reduced abilities to cause disease, but remain capable of providing immunity in humans. As such, live-attenuated viruses represent one of the effective strategies for the development of vaccines against wide-spread viral infections.  The genomic RNA of the virus must be modified with a methyl group in order to be copied by infected cells, and this methyl group is added by enzymes using the natural compound S-adenosylmethionine (AdoMet). Dr. Mehtaâ€™s project engineers SARS-CoV-2 particles that use synthetic forms of AdoMet (called xAdoMet) for this critical methylation step. The resulting engineered SARS-CoV-2* is a live virus in a laboratory, where xAdoMet can be added as a required supplement. The SARS-CoV-2*, however, cannot reproduce in normal cells, where xAdoMet is not present, but can still result in an immune response in an infected patient. The impact on society is that a unique platform is engineered for the development of vaccines to address viral diseases, including the COVID-19 pandemic.  The broader impacts of this project include the strong cross-disciplinary training of graduate students.&lt;br/&gt;&lt;br/&gt;This goal of this study is to develop live attenuated SARS-CoV-2 particles that are dependent on an unnatural version of an essential cofactor for its replication that is added in a laboratory setting, but not available in the infected host. SARS-CoV-2 requires S-adenosylmethionine (AdoMet) as a cofactor for a critical methylation of the viral RNA by a methyl transferase in order to translate its genes and replicate its genome. Through this project, a strain of the coronavirus (SARS-CoV-2*) is engineered that utilizes and is dependent on an unnatural analogue of AdoMet (xAdoMet) for the critical methylation reactions. Such a virus requires supplements of xAdoMet in a laboratory in order to replicate. Once injected into a host, this viral strain can infect a cell and potentially induce an immune response in the host, but cannot replicate in the absence of exogenous supplementation with xAdoMet. The objectives are to synthesize a series of xAdoMet compounds; use the xAdoMet compounds to engineer SARS-CoV-2* through directed evolution; and test the live attenuated virus for induction of immune response in cell culture. The AdoMet-dependent methylation mechanism is conserved in all known coronavirus pathogens and, therefore, has the potential to serve as a far-reaching and modular platform for vaccine development well beyond SARS-CoV-2.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>07/08/2020</MinAmdLetterDate>
<MaxAmdLetterDate>07/08/2020</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.049</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2037695</AwardID>
<Investigator>
<FirstName>Angad</FirstName>
<LastName>Mehta</LastName>
<PI_MID_INIT>P</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Angad P Mehta</PI_FULL_NAME>
<EmailAddress>apm8@illinois.edu</EmailAddress>
<PI_PHON>2173009925</PI_PHON>
<NSF_ID>000827397</NSF_ID>
<StartDate>07/08/2020</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>University of Illinois at Urbana-Champaign</Name>
<CityName>Champaign</CityName>
<ZipCode>618207406</ZipCode>
<PhoneNumber>2173332187</PhoneNumber>
<StreetAddress>1901 South First Street</StreetAddress>
<StreetAddress2><![CDATA[Suite A]]></StreetAddress2>
<CountryName>United States</CountryName>
<StateName>Illinois</StateName>
<StateCode>IL</StateCode>
<CONGRESSDISTRICT>13</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>IL13</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>041544081</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>UNIVERSITY OF ILLINOIS</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM>041544081</ORG_PRNT_DUNS_NUM>
</Institution>
<Performance_Institution>
<Name><![CDATA[University of Illinois at Urbana-Champaign Henry Admin Bldg]]></Name>
<CityName>Urbana</CityName>
<StateCode>IL</StateCode>
<ZipCode>618013620</ZipCode>
<StreetAddress><![CDATA[506 Wright Street]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Illinois</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>13</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>IL13</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>6883</Code>
<Text>Chemistry of Life Processes</Text>
</ProgramElement>
<ProgramReference>
<Code>096Z</Code>
<Text>COVID-19 Research</Text>
</ProgramReference>
<ProgramReference>
<Code>7914</Code>
<Text>RAPID</Text>
</ProgramReference>
<Appropriation>
<Code>0120</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2020~200000</FUND_OBLG>
</Award>
</rootTag>
